TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Brief Summary: The aim of this study is to evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day all cause mortality.


Options:
A: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
D: Arm Label: heparin; Type: PLACEBO_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Arm Label: citrate regional anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: citrate regional anticoagulation | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): heparin | Intervention Type: DEVICE; Name: citrate regional anticoagulation; Assigned to Arm(s): citrate regional anticoagulation, heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
Brief Summary: The aim of this study is to evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day all cause mortality.


Options:
A: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate
D: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure: A Multicentre Randomized Trial
Brief Summary: Multicentre, open, randomised, and controlled trial conducted in patients diagnosed with acute on chronic liver failure (ACLF) who meet inclusion/exclusion criteria.The objective of GRAFT-trial is to evaluate efficacy and safety of subcutaneously administered granulocyte colony-stimulating factor (G-CSF) in patients with ACLF. All patients will receive standard medical care for ACLF according to the guidelines. Patients in the experimental arm additional receive subcutaneous injections of G-CSF.


Options:
A: Arm Label: Standard Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Medical Therapy | Arm Label: G-CSF + Standard Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF, Drug: Standard Medical Therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Standard Medical Therapy | Intervention Type: DRUG; Name: Standard Medical Therapy; Assigned to Arm(s): G-CSF + Standard Medical Therapy, Standard Medical Therapy
B: Arm Label: G-CSF+EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+EPO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF+EPO; Assigned to Arm(s): G-CSF+EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Standard Medical Therapy + G CSF Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF | Arm Label: Standard Medical Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Standard Medical Therapy + G CSF Therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Medical Therapy + Placebo
D: Arm Label: G-CSF + Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: G-CSF, Other: Standard therapy | Arm Label: Standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): G-CSF + Standard therapy, Standard therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis (CONNECT Trial): A Multicentre Randomized Controlled Trial
Brief Summary: Compared to hemodialysis, patients on peritoneal dialysis live longer and healthier, have a higher quality of life and cost approximately $40,000 less to the healthcare system per patient per year. However, only 18% of dialysis patients in Canada currently use peritoneal dialysis because patients often feel isolated from the healthcare team and lack the confidence to manage treatments by themselves. This study will assess a telehome monitoring system (eQ Connect™), allowing for up-to-date data transmission and digital interaction between the patients at home and their healthcare team. From the patients' perspective, this technology is an easier way to communicate with their healthcare providers, track their treatment and supplies, and receive training and support. From the providers' perspective, eQ Connect™ delivers up-to-date patient data and provides an efficient way to keep track of the patients' progress. This intervention has the potential to improve the patients' clinical outcomes, quality of life, reduce the costs of dialysis to the healthcare system and ultimately empower patients to start and stay on peritoneal dialysis.


Options:
A: Arm Label: Computerised CBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy, Behavioral: Telephone support | Arm Label: Computerised CBT without therapist support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Computerised Cognitive Behavioural Therapy | Intervention Type: BEHAVIORAL; Name: Computerised Cognitive Behavioural Therapy; Assigned to Arm(s): Computerised CBT with therapist support, Computerised CBT without therapist support | Intervention Type: BEHAVIORAL; Name: Telephone support; Assigned to Arm(s): Computerised CBT with therapist support
B: Arm Label: Telehome Monitoring; Type: EXPERIMENTAL; Interventions: Device: Telehome Monitoring | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehome Monitoring; Assigned to Arm(s): Telehome Monitoring
C: Arm Label: Teleconsultation; Type: OTHER; Interventions: Other: Teleconsultation / Standard consultation | Arm Label: Standard consultation; Type: OTHER; Interventions: Other: Teleconsultation / Standard consultation | Intervention Type: OTHER; Name: Teleconsultation / Standard consultation; Assigned to Arm(s): Standard consultation, Teleconsultation
D: Arm Label: Alert; Type: EXPERIMENTAL; Interventions: Other: Alert | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Alert; Assigned to Arm(s): Alert

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: On Demand vs Continuous Treatment of Endoscopy Negative Subjects With Gastroesophageal Reflux Disease (GERD) With Esomeprazole 20-mg Once Daily Over a 6 Months Long Term Treatment Phase. An Open, Randomised, Multicenter Study. NEED.
Brief Summary: The purpose of this study is to compare on demand with continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD), with esomeprazole 20-mg once daily, with regards to willingness to continue in the study as a result of satisfactory treatment over a six-month long term management period, after initial symptom relief.


Options:
A: Arm Label: On demand 20 mg esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Continuous 20 mg esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Continuous 20 mg esomeprazole, On demand 20 mg esomeprazole
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexlansoprazole MR QD | Intervention Type: DRUG; Name: Dexlansoprazole MR QD; Assigned to Arm(s): 1
C: Arm Label: GERD Los Angeles A and B-4 week group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole 40 mg | Arm Label: GERD Los Angeles A and B-8-week group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole 40 mg | Intervention Type: DRUG; Name: Esomeprazole 40 mg; Assigned to Arm(s): GERD Los Angeles A and B-4 week group, GERD Los Angeles A and B-8-week group
D: Arm Label: esomeprazole; Type: NO_INTERVENTION; Interventions: Drug: esomeprazole, Procedure: Helicobacter pylori c-13 breath test | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: esomeprazole, Procedure: Helicobacter pylori c-13 breath test | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole, placebo drug | Intervention Type: PROCEDURE; Name: Helicobacter pylori c-13 breath test; Assigned to Arm(s): esomeprazole, placebo drug

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial
Brief Summary: The purpose of this study is to determine whether Fumaria Parviflora L. can minimize severity of pruritus in patients with end-stage renal disease.


Options:
A: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): montelukast | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin 75mg daily for 12 weeks | Arm Label: fexofenadine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fexofenadine 60 mg daily for 12 weeks | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin 75mg daily for 12 weeks; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: fexofenadine 60 mg daily for 12 weeks; Assigned to Arm(s): fexofenadine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Wheat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Wheat | Arm Label: Fumaria; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaria | Intervention Type: DRUG; Name: Wheat; Assigned to Arm(s): Wheat | Intervention Type: DRUG; Name: Fumaria; Assigned to Arm(s): Fumaria
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: cromolyn sodium | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: cromolyn sodium; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Virtual Reality Based Training on Posture Stability in Individuals With Parkinson's Disease
Brief Summary: The present study is to examine the effects of a virtual reality based balance training using the Kinect sensor on postural stability and functional balance in individuals with Parkinson's disease.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy aimed to improve Physical Activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy aimed to move safely | Intervention Type: OTHER; Name: Physical therapy aimed to move safely; Assigned to Arm(s): B | Intervention Type: OTHER; Name: Physical Therapy aimed to improve Physical Activity; Assigned to Arm(s): A
B: Arm Label: Virtual reality based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual reality based intervention | Arm Label: Conventional intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional intervention | Intervention Type: BEHAVIORAL; Name: Virtual reality based intervention; Assigned to Arm(s): Virtual reality based intervention | Intervention Type: BEHAVIORAL; Name: Conventional intervention; Assigned to Arm(s): Conventional intervention
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Multidisciplinary Care | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Multidisciplinary Care; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
D: Arm Label: Virtual Reality Training; Type: EXPERIMENTAL; Interventions: Device: Balance Training with Nintendo Wii Fit | Arm Label: Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: Balance Training with Nintendo Wii Fit; Assigned to Arm(s): Virtual Reality Training | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Physical Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System: Multi-site Implementation Study
Brief Summary: This is a multi site experiment to evaluate the impact of various strategies for increasing the use of evidence based screening, assessment and linkage to substance use treatment. All sites collect baseline data and receive a core intervention. Half are then randomly assigned to get an additional year of coaching to facilitate implementation.


Options:
A: Arm Label: Usual Case Management (UCM); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program | Arm Label: UCM + Smartphone; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program, Behavioral: Unlimited Smartphone | Arm Label: Smartphone Based Case Management (SPCM); Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Case Management at Homeless Recovery Program, Behavioral: Unlimited Smartphone, Behavioral: Smartphone Based Case Management (SPCM) app | Intervention Type: BEHAVIORAL; Name: In-Person Case Management at Homeless Recovery Program; Assigned to Arm(s): Smartphone Based Case Management (SPCM), UCM + Smartphone, Usual Case Management (UCM) | Intervention Type: BEHAVIORAL; Name: Unlimited Smartphone; Assigned to Arm(s): Smartphone Based Case Management (SPCM), UCM + Smartphone | Intervention Type: BEHAVIORAL; Name: Smartphone Based Case Management (SPCM) app; Assigned to Arm(s): Smartphone Based Case Management (SPCM)
B: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Core; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core | Arm Label: Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Core, Behavioral: Enhanced | Intervention Type: BEHAVIORAL; Name: Core; Assigned to Arm(s): Core, Enhanced | Intervention Type: BEHAVIORAL; Name: Enhanced; Assigned to Arm(s): Enhanced

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System: Multi-site Implementation Study
Brief Summary: This is a multi site experiment to evaluate the impact of various strategies for increasing the use of evidence based screening, assessment and linkage to substance use treatment. All sites collect baseline data and receive a core intervention. Half are then randomly assigned to get an additional year of coaching to facilitate implementation.


Options:
A: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Core; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core | Arm Label: Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Core, Behavioral: Enhanced | Intervention Type: BEHAVIORAL; Name: Core; Assigned to Arm(s): Core, Enhanced | Intervention Type: BEHAVIORAL; Name: Enhanced; Assigned to Arm(s): Enhanced
C: Arm Label: Methadone plus Patient Navigation; Type: EXPERIMENTAL; Interventions: Drug: Methadone, Behavioral: Patient Navigation | Arm Label: Methadone; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: Enhanced Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Treatment as Usual (ETAU) | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone, Methadone plus Patient Navigation | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Methadone plus Patient Navigation | Intervention Type: BEHAVIORAL; Name: Enhanced Treatment as Usual (ETAU); Assigned to Arm(s): Enhanced Treatment as Usual
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient and Provider Engagement and Empowerment Through Technology (P2E2T2) Program to Improve Health in Diabetes
Brief Summary: The overall goal of this proposal is to enhance the supports and resources available to patients with diabetes to assist them to achieve their health goals. The investigators will evaluate an innovative program that uses nurse health coaching, motivational interviewing techniques, wireless sensors and mobile health (mHealth) technology. In this program, patients will receive timely, tailored nurse coaching feedback to facilitate behavior change using mHealth technology, thus bridging bidirectional exchange of meaningful information among patient, nurse coach and provider. The investigators will conduct a randomized controlled trial among patients receiving chronic disease management at the University of California Davis(UC Davis) Primary Care Network. The patients who are eligible for inclusion in the study will be randomized to one of two arms of the trial: 1) Usual care (Care Coordination) administered by UC Davis Health Management and Education; or 2) the Patient and Provider Engagement and Empowerment through Technology (P2E2T2) Program to Improve Health in Diabetes. The hypothesis is that patients in the P2E2T2 arm of the study will be more engaged in identifying and achieving health goals related to their diabetes and will achieve better health outcomes compared to patients receiving usual care.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminders of medicines intake | Intervention Type: BEHAVIORAL; Name: SMS reminders of medicines intake; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
D: Arm Label: Usual Care-Chronic Disease Management; Type: SHAM_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: P2E2T2 Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: P2E2T2 Program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care-Chronic Disease Management | Intervention Type: BEHAVIORAL; Name: P2E2T2 Program; Assigned to Arm(s): P2E2T2 Program

Answer: D